Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01472185 · ClinicalTrials.gov registry record · Phase 3
Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus
A Phase 3 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 465
- Enrollment target
NCT01472185: Completed Phase 3 study, sponsored by Gilead Sciences.
NCT01472185 is a Phase 3 study that has completed, run by Gilead Sciences. The registered enrollment target is 465 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (40% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01472185, a Phase 3 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 465 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled, parallel-group, multi-center study to determine the effect of ranolazine when given as monotherapy on glycemic control in subjects with type 2 diabetes mellitus (T2DM) who were inadequately controlled with diet and exercise alone and who are treatment naive to antihyperglycemic therapy or have not received antihyperglycemic therapy in the 90 days (or thiazolidinediones \[TZDs\] for at least 24 weeks) prior to screening, and to characterize the relationship between HbA1c reduction and other glycemic parameters in subjects with T2DM.
Primary Outcome
The average (mean) change from baseline in HbA1c at Week 24 was analyzed.
Interventions
- DRUG Placebo
- BEHAVIORAL Exercise
- BEHAVIORAL Diet
- DRUG Ranolazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 465 participants |
| Start Date | 2011-11 |
| Est. Completion | 2013-10 |
| Phase | Phase 3 |
What the finished NCT01472185 record still lists
NCT01472185 is an interventional study that assigns participants to a tested intervention. The registered 465 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (40% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01472185 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01472185 about?
NCT01472185 is a clinical study titled "Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus". This is a randomized, double-blind, placebo-controlled, parallel-group, multi-center study to determine the effect of ranolazine when given as monotherapy on glycemic control in subjects with type 2 diabetes mellitus (T2DM) who were inadequately controlled with diet and exercise alone and who are tr...
What is the current status of trial NCT01472185?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 465 participants. The study started on 2011-11. Estimated completion is 2013-10.
What interventions are being tested in trial NCT01472185?
The interventions under investigation include: Placebo (DRUG), Exercise (BEHAVIORAL), Diet (BEHAVIORAL), Ranolazine (DRUG).
Who is sponsoring clinical trial NCT01472185?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01472185's enrollment target sits among peer trials
465 819th of 2000 higher than 1,180 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06717698 · 465 participants · Phase 2
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
- NCT07420283 · 465 participants · Phase 2
A Study of Brenipatide in Participants With Opioid Use Disorder
- NCT05312879 · 466 participants · Phase 2
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease
- NCT06917404 · 466 participants · Phase 3
A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia